

# Rohit Loomba

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4715673/publications.pdf](https://exaly.com/author-pdf/4715673/publications.pdf)

Version: 2024-02-01

159  
papers

6,868  
citations

79946

39  
h-index

80575

73  
g-index

180  
all docs

180  
docs citations

180  
times ranked

8414  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2024, 22, 81-90.e4.	4.7	6
2	Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes. <i>Hepatology</i> , 2024, 79, 1098-1106.	8.1	4
3	Low liver fat in nonalcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 80-88.	3.7	8
4	Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study. <i>Hepatology Communications</i> , 2024, 8, .	4.4	2
5	Cost-Effectiveness Analysis of Hepatocellular Carcinoma Surveillance in Nonalcoholic Fatty Liver Disease Cirrhosis Using US Visualization Score-Triggered Abbreviated MRI. <i>American Journal of Gastroenterology</i> , 2024, 119, 1326-1336.	0.4	3
6	Letter: Are we forgetting the importance of steatosis in steatotic liver disease? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 297-298.	3.7	0
7	Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 150-156.	3.7	23
8	Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 666-679.	3.7	11
9	Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 730-741.	3.7	2
10	From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research. <i>Nature Metabolism</i> , 2024, 6, 600-602.	11.4	9
11	Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. <i>Hepatology</i> , 2024, 79, 1212-1219.	8.1	16
12	Review article: Current indications and selection criteria for early liver transplantation in severe alcohol-associated hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 1049-1061.	3.7	0
13	Prevalence of at-risk MASH, MASH and alcohol-associated steatotic liver disease in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 1271-1281.	3.7	6
14	Review article: New developments in biomarkers and clinical drug development in alpha1 antitrypsin deficiency-related liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 1183-1195.	3.7	0
15	Reply: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. <i>Hepatology</i> , 2024, 80, E9-E10.	8.1	0
16	Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD. <i>Hepatology Communications</i> , 2024, 8, .	4.4	1
17	Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 1521-1526.	3.7	2
18	New and emerging treatments for metabolic dysfunction-associated steatohepatitis. <i>Cell Metabolism</i> , 2024, 36, 912-926.	15.8	4

#	ARTICLE	IF	CITATIONS
19	Editorial: Crystallising the burden of steatotic liver diseaseâ€”Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 1294-1295.	3.7	0
20	Randomised clinical trial: Design of the SYNERGYâ€”NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunctionâ€”associated steatohepatitis and modification of screening strategy to reduce screen failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 60, 17-32.	3.7	1
21	The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 60, 369-377.	3.7	2
22	Response to Tapper and Chhatwal. <i>American Journal of Gastroenterology</i> , 2024, 119, 1205-1206.	0.4	0
23	Integrating genetic and socioeconomic data to predict the progression of nonalcoholic fatty liver disease. <i>American Journal of Biological Anthropology</i> , 2024, 184, .	1.2	0
24	Monitoring disease progression in metabolic dysfunctionâ€”associated steatotic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, .	3.7	0
25	Methods and validation of velacur determined fat fraction in patients with MASLD. <i>WFUMB Ultrasound Open</i> , 2024, 2, 100061.	0.0	0
26	Global prevalence of advanced liver fibrosis and cirrhosis in the general population: a systematic review and meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2024, , .	4.7	0
27	Reproducibility and Repeatability of US Shear-Wave and Transient Elastography in Nonalcoholic Fatty Liver Disease. <i>Radiology</i> , 2024, 312, .	8.8	0
28	Cover Image. <i>Liver International</i> , 2024, 44, .	4.0	0
29	Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 380-387.e3.	4.7	18
30	Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 931-939.e5.	4.7	65
31	Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1169-1177.	4.7	23
32	Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2682-2685.e4.	4.7	20
33	Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH. <i>Hepatology</i> , 2023, 77, 1150-1163.	8.1	60
34	Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants. <i>American Journal of Gastroenterology</i> , 2023, 118, 645-653.	0.4	6
35	Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. <i>Gut</i> , 2023, 72, 581-589.	13.7	42
36	Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 37-49.	18.1	141

#	ARTICLE	IF	CITATIONS
37	MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials. <i>Radiology</i> , 2023, 306, .	8.8	4
38	Review article: the role of <scp>HSD17B13</scp> on global epidemiology, natural history, pathogenesis and treatment of <scp>NAFLD</scp>. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 37-51.	3.7	22
39	A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. <i>Journal of Hepatology</i> , 2023, 78, 471-478.	3.9	91
40	A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2023, 78, 684-692.	3.9	24
41	A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 304-312.	3.7	19
42	Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 600-609.	3.7	34
43	Prevalence and factors associated with liver fibrosis among first-degree relatives of Mexican Americans with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 378-386.	3.7	7
44	Secondary bile acids improve risk prediction for noninvasive identification of mild liver fibrosis in nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 872-885.	3.7	12
45	AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2023, 77, 1797-1835.	8.1	620
46	Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019. <i>Hepatology</i> , 2023, 78, 1168-1181.	8.1	15
47	Reply to: "Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues". <i>Journal of Hepatology</i> , 2023, 78, e168-e169.	3.9	0
48	Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2789-2796.	4.7	9
49	Global epidemiology of cirrhosis – aetiology, trends and predictions. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 388-398.	18.1	165
50	Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. <i>Hepatology</i> , 2023, 78, 1896-1906.	8.1	10
51	Meta-analysis: Prevalence of significant or advanced fibrosis in adults with alpha-1 antitrypsin deficiency. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 152-158.	3.7	2
52	Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening. <i>Hepatology</i> , 2023, 78, E91-E92.	8.1	0
53	Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study. <i>Hepatology</i> , 2023, 78, 1858-1866.	8.1	7
54	Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study. <i>Gastroenterology</i> , 2023, 165, 463-472.e5.	1.4	54

#	ARTICLE	IF	CITATIONS
55	Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 229-237.	3.7	6
56	Randomized, Controlled Trial of the FGF21 Analogue Pegzofermin in NASH. <i>New England Journal of Medicine</i> , 2023, 389, 998-1008.	30.1	100
57	An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. <i>Journal of Hepatology</i> , 2023, 79, 592-604.	3.9	14
58	Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. <i>Hepatology</i> , 2023, 78, 1223-1239.	8.1	20
59	Reply: ELF in the risk stratification of NAFLD—Are the ELF thresholds suggested by the AASLD guidelines appropriate?. <i>Hepatology</i> , 2023, 78, E103-E104.	8.1	1
60	Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 585-592.	3.7	11
61	Editorial: Will MRI-PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 366-367.	3.7	1
62	Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. <i>Gut</i> , 2023, 72, 2138-2148.	13.7	40
63	Reply to: "Non-invasive testing for advanced fibrosis in patients with diabetes with fatty liver disease needs further evaluation of cut-off values" <i>Journal of Hepatology</i> , 2023, , .	3.9	0
64	Hepatocellular carcinoma surveillance utilization, barriers and the impact of changing aetiology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 797-809.	18.1	41
65	Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study. <i>Journal of Hepatology</i> , 2023, 79, 1366-1373.	3.9	4
66	MEFIB index and MAST score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease—Individual participant data meta-analyses. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 856-865.	3.7	5
67	Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. <i>Nature Medicine</i> , 2023, 29, 2656-2664.	30.1	26
68	Inverse correlation between vitamin D and CRP levels in alopecia areata: A pilot study. <i>Journal of Cosmetic Dermatology</i> , 2023, 22, 3176-3180.	1.7	0
69	Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency Evaluation. <i>Cancer Research Communications</i> , 2023, 3, 1959-1965.	1.8	0
70	Editorial: Can liver fat quantification stratify cardiovascular risk in type 2 diabetes? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 1109-1110.	3.7	0
71	Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. <i>Gut</i> , 2022, 71, 983-990.	13.7	66
72	Magnetic resonance elastography plus Fibrosis-4 versus FibroScan—aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Hepatology</i> , 2022, 75, 661-672.	8.1	37

#	ARTICLE	IF	CITATIONS
73	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. <i>Hepatology Communications</i> , 2022, 6, 461-472.	4.4	11
74	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	18.1	386
75	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548.	3.9	87
76	Utilizing Macrosteatotic Allografts for Nonalcoholic Steatohepatitis Recipients. <i>Liver Transplantation</i> , 2022, 28, 552-553.	2.8	0
77	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2022, 162, 680-688.	1.4	66
78	Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm. <i>Liver Transplantation</i> , 2022, 28, 670-677.	2.8	3
79	NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH. <i>Hepatology</i> , 2022, 76, 172-185.	8.1	30
80	Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. <i>Hepatology</i> , 2022, 75, 1647-1661.	8.1	45
81	Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. <i>Nature Medicine</i> , 2022, 28, 430-432.	30.1	36
82	Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 292-301.	3.7	49
83	Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 820-827.	3.7	36
84	Review article: current and emerging therapies for the management of cirrhosis and its complications. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1099-1115.	3.7	25
85	Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1076-1087.	3.7	18
86	Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 894-907.	3.7	40
87	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD). <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1441-1451.	3.7	10
88	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	8.1	18
89	Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD. <i>Radiology</i> , 2022, 304, 75-82.	8.8	16
90	Editorial: screening for hepatocellular carcinoma in NAFLD cirrhosis—towards abbreviated MRI alternative in patients with obesity? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1212-1213.	3.7	0

#	ARTICLE	IF	CITATIONS
91	Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210938.	3.2	23
92	Letter: noninvasive prediction models to exclude cirrhosis in <sc>NAFLD</sc> â€”not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 182-183.	3.7	0
93	Current therapies and new developments in NASH. Gut, 2022, 71, 2123-2134.	13.7	106
94	Living in the nonalcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives. Alimentary Pharmacology and Therapeutics, 2022, 56, 570-579.	3.7	11
95	Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. Gastroenterology, 2022, 163, 1079-1089.e5.	1.4	67
96	Title is missing!. The Volunteer Management Report, 2022, 27, .	0.0	0
97	Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. Journal of Hepatology, 2022, 77, 1482-1490.	3.9	55
98	Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 2274-2283.e5.	4.7	120
99	MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut, 2021, 70, 1946-1953.	13.7	92
100	Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD. Clinical Gastroenterology and Hepatology, 2021, 19, 2673-2674.e3.	4.7	9
101	The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology, 2021, 73, 126-143.	8.1	65
102	Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 223-238.	18.1	1,026
103	Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology, 2021, 73, 548-559.	8.1	61
104	NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology, 2021, 73, 2028-2038.	8.1	97
105	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology, 2021, 74, 20-30.	3.9	93
106	Emerging Metabolic and Transcriptomic Signature of PNPLA3-Associated NASH. Hepatology, 2021, 73, 1248-1250.	8.1	4
107	The impact of genetic risk on liver fibrosis in nonalcoholic fatty liver disease as assessed by magnetic resonance elastography. Alimentary Pharmacology and Therapeutics, 2021, 54, 68-77.	3.7	21
108	Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States. Hepatology, 2021, 74, 1509-1522.	8.1	12



#	ARTICLE	IF	CITATIONS
109	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.	1.4	118
110	Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 880-889.	3.7	57
111	Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1150-1161.	3.7	103
112	Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. <i>Hepatology</i> , 2021, 74, 2241-2250.	8.1	54
113	Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor $\alpha$ modulator (SPPARM $\alpha$ ), versus placebo in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1263-1277.	3.7	117
114	Links between gut microbiome composition and fatty liver disease in a large population sample. <i>Gut Microbes</i> , 2021, 13, 1-22.	10.6	45
115	Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1030-1037.	3.7	45
116	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Nature Medicine</i> , 2021, 27, 1825-1835.	30.1	127
117	Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1498-1498.	3.7	0
118	Unterschiedliche Rekonstruktionen eines "alten Problems". , 2021, , 15-45.		0
119	A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. <i>Science Translational Medicine</i> , 2021, 13, eabg8116.	13.4	38
120	Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , 2021, 13, eabg8117.	13.4	28
121	Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease – simply associated or more complicated? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1230-1231.	3.7	0
122	Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging – Proton Density Fat Fraction as the Standard. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1842-1850.e6.	4.7	40
123	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , 2020, 72, 1819-1837.	8.1	17
124	Elevated Glycated Hemoglobin Is Associated With Liver Fibrosis, as Assessed by Elastography, in a Population-Based Study of Mexican Americans. <i>Hepatology Communications</i> , 2020, 4, 1793-1801.	4.4	18
125	Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1200-1201.	3.7	0
126	Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1305-1320.	3.7	114



#	ARTICLE	IF	CITATIONS
127	Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1149-1159.	3.7	118
128	Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092390.	3.2	29
129	Advances in non-invasive assessment of hepatic fibrosis. <i>Gut</i> , 2020, 69, 1343-1352.	13.7	208
130	Collagen biology and non-invasive biomarkers of liver fibrosis. <i>Liver International</i> , 2020, 40, 736-750.	4.0	127
131	Multicenter Validation of Association Between Decline in MRIâ€PDFF and Histologic Response in NASH. <i>Hepatology</i> , 2020, 72, 1219-1229.	8.1	91
132	AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. <i>Gastroenterology</i> , 2020, 158, 1822-1830.	1.4	227
133	Have incidence rates of liver cancer peaked in the United States?. <i>Cancer</i> , 2020, 126, 3151-3155.	4.1	30
134	Editorial: evolving histological assessment of NASH. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1245-1246.	3.7	0
135	Letter: probiotics? Yes, but which ones? Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 968-968.	3.7	0
136	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1100-1111.	3.7	30
137	Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 144-158.	3.7	58
138	Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 183-193.	3.7	88
139	Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 645-656.	3.7	55
140	Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis. <i>Journal of Immunology</i> , 2018, 201, 3017-3035.	0.8	71
141	Editorial: role of leucineâ€metforminâ€sildenafil combination in the treatment of nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 378-379.	3.7	1
142	Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 844-854.	3.7	23
143	Editorial: further evidence for the use of advanced magnetic resonance imaging techniques to monitor <sc>NAFLD</sc> â€ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1271-1272.	3.7	0
144	Editorial: non-alcoholic fatty liver diseaseâ€a pandemic in need of novel treatments and endpoints. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 65-66.	3.7	0

#	ARTICLE	IF	CITATIONS
145	Management and dissemination of MS proteomic data with PROTEOMICSdb: Example of a quantitative comparison between methods of protein extraction. <i>Proteomics</i> , 2013, 13, 1457-1466.	3.0	25
146	Rapid Label-free Protein Detection Arrays on Coated Silicon Wafers. <i>Materials Research Society Symposia Proceedings</i> , 2006, 951, 7.	0.1	0
147	Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 0, , .	3.7	3
148	Diagnostic Ability of Simple Noninvasive Blood Tests to Predict Increased Liver Stiffness in People Living With HIV and Steatotic Liver Disease. <i>American Journal of Gastroenterology</i> , 0, , .	0.4	0
149	MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH. <i>Gut</i> , 0, , gutjnl-2023-331401.	13.7	5
150	Non-Hispanic Black Persons With Nonalcoholic Fatty Liver Disease Have Lower Rates of Advanced Fibrosis, Cirrhosis, and Liver-Related Events Even After Controlling for Clinical Risk Factors and PNPLA3 Genotype. <i>American Journal of Gastroenterology</i> , 0, , .	0.4	2
151	High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort. <i>American Journal of Gastroenterology</i> , 0, , .	0.4	2
152	PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease. <i>Hepatology</i> , 0, , .	8.1	0
153	Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. <i>New England Journal of Medicine</i> , 0, , .	30.1	15
154	Application of Novel Biomarkers in MASLD: Precision Medicine Based Approach. <i>Seminars in Liver Disease</i> , 0, , .	3.7	0
155	Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis. <i>Hepatology</i> , 0, , .	8.1	0
156	Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study. <i>Hepatology</i> , 0, , .	8.1	0
157	Dynamic pattern of postprandial bile acids in paediatric non-alcoholic fatty liver disease. <i>Liver International</i> , 0, , .	4.0	0
158	Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA. <i>Gut</i> , 0, , gutjnl-2024-332917.	13.7	0
159	The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints. <i>American Journal of Gastroenterology</i> , 0, , .	0.4	1